VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
FULC
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
FULCFulcrum Therapeutics, Inc.
$3.75$203M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
FULC logo

Fulcrum Therapeutics, Inc.

FULC
NASDAQ · Neuroscience Biotech
$3.75
At close - Nov 17, 4:00 PM EST - USD
Market Cap$203M
P/E-3.7x
52W High$15.74
Volume1.31M
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q2

Milestone Dependency Masks Sub-Three-Quarter Cash Runway

Fulcrum Therapeutics presents a pre-revenue, asset-light research platform whose ten-quarter history is defined by a single $80.0M milestone quarter in 2024Q2 (65.6% operating margin, $0.87 diluted EPS) against operating losses near $20M in every other period, most recently -$19.9M in 2026Q2.

GrowthContracting
ProfitabilityNegative
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

FULC price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

7/12 Beats

EPS beat 7 of last 12 quarters

02

Valuation risk

-111% Peers

P/E is 111% below peer median

03

Market leadership

RS 25 · Lag

Laggard (Underperforming 75% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 12

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
FULC-65.66%
S&P 500 (^GSPC)+7.21%
1-Year Return
FULC-61.14%
S&P 500 (^GSPC)+10.03%
3-Year Return
FULC-9.64%
S&P 500 (^GSPC)+54.63%
5-Year Return
FULC-78.50%
S&P 500 (^GSPC)+60.53%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
-
Net income FY25
-$75M-670.0% YoY
Free cash flow FY25
-$60M-2319.0% YoY
Operating margin FY25
-
ROIC (FY25)-36.2%
Avg ROIC 5Y-38.1%
ROE (TTM)-23.6%
Piotroski Score3 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate7/12 (58%)
Revenue Beat Rate2/12 (100%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 12, 2026
-$0.11+0.0%
vs -$0.11
—
vs —
Q3 2026
Jul 30, 2026
-$0.34-39.7%
vs -$0.24
—
vs —
Q2 2026
Apr 27, 2026
-$0.25+19.4%
vs -$0.31
—
vs —
Q1 2026
Feb 24, 2026
-$0.31+0.0%
vs -$0.31
—
vs —
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Defense World·Oct 21, 2026
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Stock Has Average Target Price of $8.20

Shares of Fulcrum Therapeutics, Inc. (NASDAQ: FULC - Get Free Report) have been assigned an average recommendation of "Reduce" from the twelve research firms that are presently covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and one has issued a

GuruFocus·Oct 13, 2026
Are BWIN, PTC, FULC, PRTH Obtaining Fair Deals for their Shareholders?

Are BWIN, PTC, FULC, PRTH Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Oct. 12, 2026Insiders may stand to receive substantial financial bene

Newsfile Corp·Oct 8, 2026
Kaplan Fox is Investigating Claims Against Fulcrum Therapeutics, Inc. (FULC) on Behalf of Investors

New York, New York--(Newsfile Corp. - October 8, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.

Newsfile Corp·Oct 6, 2026
Kaplan Fox Encourages Fulcrum Therapeutics, Inc. (FULC) Investors Who Suffered Losses to Learn About Their Legal Rights

New York, New York--(Newsfile Corp. - October 6, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.

Filtered for Fulcrum Therapeutics, Inc.More Headlines
04

Compare before deciding

Benchmark FULC against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Fulcrum Therapeutics, Inc. (FULC)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
FULC logoFULCFulcrum Therapeutics, Inc.Current
$3.75$202.92M-3.75-100%—-23.58%—
ARWR logoARWRArrowhead Pharmaceuticals, Inc.
$42.99$6.06B-8.41-45.65%-160.64%-172.62%—
SRPT logoSRPTSarepta Therapeutics, Inc.
$14.77$1.56B106.0315.58%0.75%1.04%—
RARE logoRAREUltragenyx Pharmaceutical Inc.
$16.70$1.64B-3.2520.13%-71.78%——
CRSP logoCRSPCRISPR Therapeutics AG
$40.15$3.87B-8.52-89.97%-1812.07%-25.59%—
EDIT logoEDITEditas Medicine, Inc.
$1.83$280.07M-3.8825.39%-144.95%-130.43%—

Compare FULC vs Peers

Fulcrum Therapeutics, Inc. (FULC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ARWR

Most directly comparable listed peer for FULC.

Scale Benchmark

vs IQV

Larger-name benchmark to compare FULC against a more recognizable public peer.

Peer Set

Compare Top 5

vs ARWR, SRPT, RARE, CRSP

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

FULC SEC Filings & Documents

Fulcrum Therapeutics, Inc. (FULC) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Jun 25, 2026·SEC

Material company update

Jun 11, 2026·SEC

Material company update

Jun 4, 2026·SEC

10-K Annual Reports

3
FY 2026

Feb 24, 2026·SEC

FY 2025

Feb 25, 2025·SEC

FY 2024

Feb 27, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Jul 30, 2026·SEC

FY 2026

Apr 27, 2026·SEC

FY 2025

Oct 29, 2025·SEC

Get notified when FULC posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

FULC Frequently Asked Questions

Fulcrum Therapeutics, Inc. (FULC) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
How fast is Fulcrum Therapeutics, Inc. growing?

Fulcrum Therapeutics, Inc. (FULC) revenue fell by 100.0% in fiscal year 2025, compared with the prior fiscal year.

Is FULC profitable?

No. Fulcrum Therapeutics, Inc. (FULC) reported a net loss of $76.3M over the trailing twelve months.

Dividend & Returns
What is FULC's return on equity?

Fulcrum Therapeutics, Inc. (FULC) had a return on equity (ROE) of -23.6% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Fulcrum Therapeutics, Inc.'s free cash flow?

Fulcrum Therapeutics, Inc. (FULC) had negative free cash flow of $65.2M over the trailing twelve months.

What if you invested $1,000 in FULC back in 2017?

Total return calculator · dividends reinvested · 9+ years of data

See returns →